Filters
CEO View | Reflecting on UKRI’s first five year strategy
In this blog post our CEO offers some opinions on UK Research and Innovation's strategy. This was first published by the BioIndustry Association.
How our culture enables scientists to bring in new technologies
Learn about the culture at bit.bio and how it enabled our manufacturing team to bring in new technology to improve our processes.
Addressing current challenges of in vitro cell models
In this blog, learn about current challenges of hiPSC-derived cell models, best approach for cell generation & future trends for human cell models.
CEO View | SynBio: the opportunity for UK Life Sciences
Our CEO writes about the importance of the synthetic biology industry as part of the UK Life Sciences vision. This was first published by the BioIndustry Association.
Meet bit.bio’s two new Vice Presidents of Translational Medicine
The translational medicine team will help bit.bio build out its cell therapy pipeline and strategy.
Giving you easy access to endless and reliable human cells
Read this blog to learn how bit.bio are offering easy access to endless and reliable human cells for research and drug discovery.
CEO Views | Business and academia - the perfect partners to achieve SDGs
Our CEO reflects on a recent UN High-Level Political Forum discussion about industry & academia collaborations to achieve sustainable development goals.
CEO View | Why did I start a healthcare and cultured meat company?
Our CEO explains how our opti-ox technology underpins not only bit.bio but also Meatable - a cultured meat company — and why we need to rethink sustainability.